[May 13, 2014] |
|
Dr. Reddy's Q4 & FY14 Financial Results
HYDERABAD, India --(Business Wire)--
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) today announced its
consolidated financial results for the fourth quarter and full year
ended March 31, 2014 under International Financial Reporting Standards
(IFRS).
Key Highlights
-
Consolidated revenues for FY 14 at Rs. 132.2 billion, year-on-year
growth of 14%.
-
Consolidated revenues for Q4 FY14 at Rs. 34.8 billion,
year-on-year growth of 4%.
-
Gross Profit Margin for FY 14 at 57.4% versus 52.1% as in FY 13.
-
Gross Profit Margins for Q4 FY14 at 57.2% versus 50.4% as in Q4
FY 13.
-
Research & Development (R&D) expenses for FY 14 at Rs. 12.4
billion, year-on-year increase of 62%. Expenses at 9.4% to revenues
versus 6.6% to revenues as in FY13.
-
Research & Development (R&D) expenses for Q4 FY14 of Rs. 4.0
billion.
-
Selling, general & administrative (SG&A) expenses for FY 14 at Rs.
38.8 billion, year-on-year increase of 13%. Expenses at 29.3% to
revenues versus 29.5% to revenues as in FY13.
-
Selling, general & administrative (SG&A) expenses for Q4 FY14
at Rs. 10.3 billion.
-
EBITDA for FY 14 of Rs. 33.2 billion, 25% of revenues; year-on-year
growth of 19%.
-
EBITDA for Q4 FY14 of Rs. 7.9 billion, 23% of revenues. Q4 FY
13 included one time settlement income of Rs. 1.2 billion received
from Nordian Inc (formerly MDS Inc).
-
Profit after tax for FY14 at Rs. 21.5 billion, 16% of revenues;
year-on-year growth of 28%
-
Profit after tax for Q4 FY14 at Rs. 4.8 billion,
14% of revenues.
-
The company launched 54 new generic products, filed 51 new product
registrations and 61 DMFs globally in FY 14.
-
The company launched 13 new generic products, filed 22 new
product registrations and 29 DMFs globally in Q4 FY14.
|
All amounts in millions, except EPS
|
All US dollar amounts based on convenience translation rate of I
USD = Rs. 60.00
|
|
Dr. Reddy's Laboratories Limited and Subsidiaries
|
Consolidated Income Statement
|
|
Particulars
|
|
|
|
FY14
|
|
FY13
|
|
Growth %
|
|
|
|
($)
|
|
(Rs.)
|
|
%
|
|
($)
|
|
(Rs.)
|
|
%
|
|
Revenues
|
|
|
|
2,203
|
|
|
132,170
|
|
|
100
|
|
|
1,938
|
|
|
116,266
|
|
|
100
|
|
|
14
|
|
Cost of revenues
|
|
|
|
939
|
|
|
56,369
|
|
|
42.6
|
|
|
928
|
|
|
55,687
|
|
|
47.9
|
|
|
1
|
|
Gross profit
|
|
|
|
1,263
|
|
|
75,802
|
|
|
57.4
|
|
|
1,010
|
|
|
60,579
|
|
|
52.1
|
|
|
25
|
|
Operating Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general & administrative expenses
|
|
|
|
646
|
|
|
38,783
|
|
|
29.3
|
|
|
571
|
|
|
34,271
|
|
|
29.5
|
|
|
13
|
|
Research and development expenses
|
|
|
|
207
|
|
|
12,402
|
|
|
9.4
|
|
|
128
|
|
|
7,673
|
|
|
6.6
|
|
|
62
|
|
Other operating expense / (income)
|
|
|
|
(24
|
)
|
|
(1,416
|
)
|
|
(1
|
)
|
|
(41
|
)
|
|
(2,479
|
)
|
|
(2
|
)
|
|
(43
|
)
|
Results from operating activities
|
|
|
|
434
|
|
|
26,032
|
|
|
19.7
|
|
|
352
|
|
|
21,112
|
|
|
18.2
|
|
|
23
|
|
Net finance income
|
|
|
|
7
|
|
|
400
|
|
|
0
|
|
|
8
|
|
|
460
|
|
|
0
|
|
|
(13
|
)
|
Share of profit of equity accounted investees, net of income tax
|
|
|
|
3
|
|
|
174
|
|
|
0
|
|
|
2
|
|
|
104
|
|
|
0
|
|
|
67
|
|
Profit before income tax
|
|
|
|
443
|
|
|
26,606
|
|
|
20.1
|
|
|
361
|
|
|
21,676
|
|
|
18.6
|
|
|
23
|
|
Income tax expense
|
|
|
|
85
|
|
|
5,094
|
|
|
3.9
|
|
|
82
|
|
|
4,900
|
|
|
4.2
|
|
|
4
|
|
Profit for the year
|
|
|
|
359
|
|
|
21,512
|
|
|
16.3
|
|
|
280
|
|
|
16,776
|
|
|
14.4
|
|
|
28
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted EPS
|
|
|
|
2.10
|
|
|
126.04
|
|
|
|
|
1.64
|
|
|
98.4
|
|
|
|
|
28
|
|
|
EBITDA Computation
|
|
Particulars
|
|
|
|
FY14
|
|
FY13
|
|
|
|
($)
|
|
(Rs.)
|
|
($)
|
|
(Rs.)
|
Profit before income tax
|
|
|
|
443
|
|
|
26,606
|
|
|
361
|
|
|
21,676
|
|
Interest income
|
|
|
|
(0
|
)
|
|
(24
|
)
|
|
(2
|
)
|
|
(94
|
)
|
Depreciation
|
|
|
|
80
|
|
|
4,804
|
|
|
64
|
|
|
3,859
|
|
Amortization & Impairment
|
|
|
|
30
|
|
|
1,794
|
|
|
40
|
|
|
2,378
|
|
EBITDA
|
|
|
|
553
|
|
|
33,180
|
|
|
464
|
|
|
27,819
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note:
Selling, general & administrative expenses, as above, includes an
impairment reversal of Rs. 497 million [FY 14] and impairment charge of
Rs. 688 million [FY 13]
|
|
|
|
|
|
|
All amounts in millions, except EPS
|
All US dollar amounts based on convenience translation rate of 1
USD = Rs. 60.00
|
|
Appendix 1: Key Balance Sheet Items
|
|
Particulars
|
|
|
|
As on 31st March 14
|
|
As on 31st March 13
|
|
|
|
($)
|
|
(Rs.)
|
|
($)
|
|
(Rs.)
|
Cash and cash equivalents and Other Investment
|
|
|
|
559
|
|
|
33,534
|
|
368
|
|
|
22,099
|
Trade receivables
|
|
|
|
551
|
|
|
33,037
|
|
533
|
|
|
31,972
|
Inventories
|
|
|
|
400
|
|
|
23,992
|
|
360
|
|
|
21,600
|
Property, plant and equipment
|
|
|
|
740
|
|
|
44,424
|
|
630
|
|
|
37,814
|
Goodwill and Other Intangible assets
|
|
|
|
245
|
|
|
14,697
|
|
234
|
|
|
14,021
|
Loans and borrowings (current & non-current)
|
|
|
|
746
|
|
|
44,742
|
|
613
|
|
|
36,760
|
Trade payables
|
|
|
|
175
|
|
|
10,503
|
|
198
|
|
|
11,862
|
Equity
|
|
|
|
1,513
|
|
|
90,801
|
|
1,213
|
|
|
72,785
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Appendix 2: Revenue Mix by Segment
|
|
Particulars
|
|
|
|
FY14
|
|
FY13
|
|
Growth %
|
|
|
|
($)
|
|
(Rs.)
|
|
%
|
|
($)
|
|
(Rs.)
|
|
%
|
|
Global Generics
|
|
|
|
1,753
|
|
|
105,164
|
|
80
|
|
1,376
|
|
|
82,563
|
|
71
|
|
27
|
|
North America
|
|
|
|
|
|
55,303
|
|
53
|
|
|
|
37,846
|
|
46
|
|
46
|
|
Europe
|
|
|
|
|
|
6,970
|
|
7
|
|
|
|
7,716
|
|
9
|
|
(10
|
)
|
India
|
|
|
|
|
|
15,713
|
|
15
|
|
|
|
14,560
|
|
18
|
|
8
|
|
Russia & Other CIS
|
|
|
|
|
|
19,819
|
|
19
|
|
|
|
16,908
|
|
20
|
|
17
|
|
Rest of World
|
|
|
|
|
|
7,359
|
|
7
|
|
|
|
5,533
|
|
7
|
|
33
|
|
PSAI
|
|
|
|
400
|
|
|
23,974
|
|
18
|
|
512
|
|
|
30,702
|
|
26
|
|
(22
|
)
|
North America
|
|
|
|
|
|
4,354
|
|
18
|
|
|
|
5,744
|
|
19
|
|
(24
|
)
|
Europe
|
|
|
|
|
|
8,770
|
|
37
|
|
|
|
12,007
|
|
39
|
|
(27
|
)
|
India
|
|
|
|
|
|
3,787
|
|
16
|
|
|
|
4,638
|
|
15
|
|
(18
|
)
|
Rest of World
|
|
|
|
|
|
7,063
|
|
29
|
|
|
|
8,313
|
|
27
|
|
(15
|
)
|
Proprietary Products & Others
|
|
|
|
51
|
|
|
3,032
|
|
2
|
|
50
|
|
|
3,001
|
|
3
|
|
1
|
|
Total
|
|
|
|
2,203
|
|
|
132,170
|
|
100
|
|
1,938
|
|
|
116,266
|
|
100
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segmental Analysis
Global Generics
Revenues from Global Generics segment for FY14 are at Rs. 105.2 billion,
year-on-year growth of 27%, primarily driven by North America and
Emerging Markets.
-
Revenues from North America for FY14 at Rs. 55.3 billion,
year-on-year growth of 46%.
-
Growth was largely driven by key launches in limited competition
space. 9 new products were launched during the year, major being
azacitidine, decitabine, zoledronic acid, donepezil 23mg and
divalproex ER.
-
Progress on market share expansion of key molecules namely
metoprolol succinate and atorvastatin.
-
13 product filings in the US during the year. Cumulatively, 62
ANDAs are pending for approval with the USFDA of which 39 are Para
IVs out of which 9 to have 'First To File' status.
-
Revenues from Emerging Markets for FY14 at Rs. 27.2 billion,
year-on-year growth of 21%.
-
Revenues from Russia at Rs. 16.3 billion, year-on-year
growth of 16%, largely driven by higher volumes of the top brands
and the OTC portfolio.
-
Revenues from CIS markets at Rs. 3.5 billion, year-on-year
growth of 22%. Continuing momentum in existing products coupled
with select launches from in-licensed portfolio.
-
Revenues from Rest of World (RoW) territories at Rs. 7.4
billion recorded year-on-year growth of 33%. Of this Venezuela has
shown strong growth despite currency devaluation in FY14.
-
Revenues from India for FY14 at Rs. 15.7
billion, year-on-year growth of 8%.
-
Growth driven by brands in chronic therapy, volume increase across
NLEM covered portfolio and new product launches.
-
IMS Mar '14, Dr Reddy's MAT Gr% 12.27% versus IPM MAT Gr% of 9.9%. (Source (News - Alert):
IMS).
-
Biosimilars portfolio stable at Rs. 1.13 billion in FY14
Pharmaceutical Services and Active Ingredients (PSAI)
-
Revenues from PSAI for FY14 at Rs. 24 billion, year-on-year decline of
22%.
-
Challenging year on the external market front due to lower demand from
key customers coupled with lesser number of launches as compared to
the previous year.
-
During the year, 61 DMFs were filed globally, including 12 in the US
and 13 in Europe. The cumulative number of DMF filings as of March 31,
2014 is 631.
Income Statement Highlights:
-
Gross profit margin at 57.4% in FY14 registered strong 530 basis
points improvement over the last year. Gross profit margin for Global
Generics (GG) and PSAI business segments are at 65.8% and 20.2%
respectively for FY14.
GG gross margin improvement
primarily on account improved mix of high margin new product launches
in North America.
-
Selling, General and Administration (SG&A) expenses at Rs. 38.8
billion, year-on-year increase of 13%. The increase is primarily on
account of annual increments, additional manpower deployment in select
areas, sales & marketing spend for events specific to the year and the
effect of rupee depreciation against multiple currencies.
-
Research & development expenses at Rs. 12.4 billion, year-on-year
growth of 62%. 9.4% of revenues in FY14 as compared to 6.6% of
revenues in FY13. The increase is in line with our planned scale-up in
development activities.
-
Net Finance income at Rs. 400 million compared to Rs. 460 million in
FY13. The change is on account of :
-
Net incremental forex benefit of Rs. 7 million
-
Incremental net interest expense of Rs. 71 million
-
EBITDA for FY14 at Rs. 33.2 billion, year-on-year growth of 19%; 25%
of revenues.
-
Profit after Tax in FY14 at Rs. 21.5 billion, year-on-year growth of
28%; 16% of revenues.
-
Diluted earnings per share in FY 14 at Rs. 126.04
-
Capital expenditure for FY14 is Rs. 10.2 billion.
The Board has recommended payment of a dividend of Rs. 18 per equity
share of face value Rs. 5/- each (360% of face value) for the year ended
March 31, 2014, subject to approval of members.
|
|
|
|
|
|
|
|
|
All amounts in millions, except EPS
|
All US dollar amounts based on convenience translation rate as
on 31st March, 2014 USD = Rs. 60.00
|
|
Appendix 3: Q4 FY4 Consolidated Income Statement
|
|
Particulars
|
|
|
|
Q4 FY14
|
|
Q4 FY13
|
|
Growth %
|
|
|
|
($)
|
|
(Rs.)
|
|
%
|
|
($)
|
|
(Rs.)
|
|
%
|
|
Revenues
|
|
|
|
580
|
|
|
34,809
|
|
|
100.0
|
|
|
557
|
|
|
33,400
|
|
|
100.0
|
|
|
4
|
|
Cost of revenues
|
|
|
|
248
|
|
|
14,887
|
|
|
42.8
|
|
|
276
|
|
|
16,554
|
|
|
49.6
|
|
|
(10
|
)
|
Gross profit
|
|
|
|
332
|
|
|
19,922
|
|
|
57.2
|
|
|
281
|
|
|
16,846
|
|
|
50.4
|
|
|
18
|
|
Operating Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general & administrative expenses
|
|
|
|
172
|
|
|
10,307
|
|
|
29.6
|
|
|
145
|
|
|
8,722
|
|
|
26.1
|
|
|
18
|
|
Research and development expenses
|
|
|
|
66
|
|
|
3,985
|
|
|
11.4
|
|
|
39
|
|
|
2,326
|
|
|
7.0
|
|
|
71
|
|
Other operating expense / (income)
|
|
|
|
(4
|
)
|
|
(226
|
)
|
|
(0.7
|
)
|
|
(27
|
)
|
|
(1,631
|
)
|
|
(4.9
|
)
|
|
(86
|
)
|
Results from operating activities
|
|
|
|
98
|
|
|
5,857
|
|
|
16.8
|
|
|
124
|
|
|
7,427
|
|
|
22.2
|
|
|
(21
|
)
|
Net finance income
|
|
|
|
3
|
|
|
163
|
|
|
0.5
|
|
|
7
|
|
|
397
|
|
|
1.2
|
|
|
(59
|
)
|
Share of profit of equity accounted investees
|
|
|
|
1
|
|
|
48
|
|
|
0.1
|
|
|
0
|
|
|
26
|
|
|
0.1
|
|
|
91
|
|
Profit before income tax
|
|
|
|
101
|
|
|
6,068
|
|
|
17.4
|
|
|
131
|
|
|
7,850
|
|
|
23.5
|
|
|
(23
|
)
|
Income tax expense
|
|
|
|
21
|
|
|
1,252
|
|
|
3.6
|
|
|
36
|
|
|
2,141
|
|
|
6.4
|
|
|
(42
|
)
|
Profit for the period
|
|
|
|
80
|
|
|
4,816
|
|
|
13.8
|
|
|
95
|
|
|
5,709
|
|
|
17.1
|
|
|
(16
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted EPS
|
|
|
|
0.47
|
|
|
28.22
|
|
|
|
|
0.56
|
|
|
33.51
|
|
|
|
|
(16
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Appendix 4: EBITDA Computation
|
|
Particulars
|
|
|
|
Q4 FY14
|
|
Q4 FY13
|
|
|
|
($)
|
|
(Rs.)
|
|
($)
|
|
(Rs.)
|
Profit before income tax
|
|
|
|
101
|
|
|
6,068
|
|
|
131
|
|
|
7,851
|
|
Interest income
|
|
|
|
(1
|
)
|
|
(82
|
)
|
|
(1
|
)
|
|
(52
|
)
|
Depreciation
|
|
|
|
22
|
|
|
1,308
|
|
|
17
|
|
|
1,049
|
|
Amortization
|
|
|
|
11
|
|
|
648
|
|
|
7
|
|
|
446
|
|
EBITDA
|
|
|
|
132
|
|
|
7,942
|
|
|
155
|
|
|
9,292
|
|
|
|
Appendix 5: Revenue Mix by Segment
|
|
|
|
|
|
Q4 FY14
|
|
Q4 FY13
|
|
Growth %
|
|
|
|
($)
|
|
(Rs.)
|
|
%
|
|
($)
|
|
(Rs.)
|
|
%
|
|
Global Generics
|
|
|
|
455
|
|
|
27,318
|
|
78
|
|
376
|
|
|
22,566
|
|
68
|
|
21
|
|
North America
|
|
|
|
|
|
14,964
|
|
55
|
|
|
|
11,413
|
|
51
|
|
31
|
|
Europe
|
|
|
|
|
|
1,774
|
|
6
|
|
|
|
1,831
|
|
8
|
|
(3
|
)
|
India
|
|
|
|
|
|
4,101
|
|
15
|
|
|
|
3,481
|
|
15
|
|
18
|
|
Russia & Other CIS
|
|
|
|
|
|
4,519
|
|
17
|
|
|
|
4,519
|
|
20
|
|
(0
|
)
|
Rest of World
|
|
|
|
|
|
1,960
|
|
7
|
|
|
|
1,322
|
|
6
|
|
48
|
|
PSAI
|
|
|
|
111
|
|
|
6,641
|
|
19
|
|
170
|
|
|
10,173
|
|
30
|
|
(35
|
)
|
North America
|
|
|
|
|
|
1,538
|
|
23
|
|
|
|
2,061
|
|
20
|
|
(25
|
)
|
Europe
|
|
|
|
|
|
2,370
|
|
36
|
|
|
|
4,396
|
|
43
|
|
(46
|
)
|
India
|
|
|
|
|
|
979
|
|
15
|
|
|
|
1,612
|
|
16
|
|
(39
|
)
|
Rest of World
|
|
|
|
|
|
1,754
|
|
26
|
|
|
|
2,105
|
|
21
|
|
(17
|
)
|
Proprietary Products & Others
|
|
|
|
14
|
|
|
851
|
|
2
|
|
11
|
|
|
661
|
|
2
|
|
29
|
|
Total
|
|
|
|
580
|
|
|
34,809
|
|
100
|
|
557
|
|
|
33,400
|
|
100
|
|
4
|
|
|
Disclaimer
This press release includes forward-looking statements, as defined in
the U.S. Private Securities Litigation Reform Act of 1995. We have based
these forward-looking statements on our current expectations and
projections about future events. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual
results to differ materially. Such factors include, but are not limited
to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand
for our products, our growth and expansion, technological change and our
exposure to market risks. By their nature, these expectations and
projections are only estimates and could be materially different from
actual results in the future.
About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses -
Pharmaceutical Services and Active Ingredients, Global Generics and
Proprietary Products - Dr. Reddy's offers a portfolio of products and
services including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Major therapeutic focus is
on gastro-intestinal, cardiovascular, diabetology, oncology, pain
management and anti-infective. Major markets include India, USA,
Russia-CIS and Europe apart from other select geographies within
Emerging Markets.
For more information, log on to: www.drreddys.com
Note: All discussions in this release are based on
consolidated IFRS financials.
[ Back To TMCnet.com's Homepage ]
|